Gnosis is proud to announce that its commitment to providing innovative solutions to global well-being and healthcare challenges has been rewarded at NutraIngredients Award 2016, winning in the Finished Product of the Year - Medical Food category with XaQuil XR from XYMOGEN, a new finished product formulated with Quatrefolic.
At Vitafoods, NutraIngredients Awards 2016 celebrated innovation and research of the global nutritional industry, awarding companies and products that, by seizing the most recent compelling nutritional needs, really bring tangible benefits to humans well-being.
XaQuil XR, formulated with Quatrefolic and developed through a fruitful partnership between XYMOGEN and Gnosis, triumphed as Finished Product of the Year in the Medical Food category.
The independent 10-person judging panel evaluated the true innovation, the validated research and the ability to recognise and fill a gap in the healthy product sector.
XaQuil XR by XYMOGEN is an innovative medical food formulated with Quatrefolic and used as an adjunctive treatment for depression. XaQuil XR fulfils the emergent scientific demand that have compelled psychiatrists to consider augmenting traditional antidepressants with the medical food L-methylfolate.
The Quatrefolic in XaQuil XR is the glucosamine salt of 5-methyltetrahydrofolate (5-MTHF), the metabolic active form of folate. The specific and patented extended-release profile of Quatrefolic was chosen to replicate what happens into the intestine to dietary folate.
The medical food industry is expanding and is driven by the rising aging population, the shift to enteral nutrition and a demand for personalised medicine. XaQuil XR offers the most bioavailable form of reduced folate available in the market, Quatrefolic, the glucosamine salt of 5-MTHF, in an innovative, orally administered, extended-release formulation.